10:57 AM EDT, 04/05/2024 (MT Newswires) -- Ocugen ( OCGN ) said Friday the Data and Safety Monitoring Board for the phase 1/2 trial of OCU410 to treat geographic atrophy has approved proceeding with a medium dose in the dose-escalation stage of the study.

The trial is evaluating the safety of sub-retinal administration of OCU410 in people with the disease, the company said.

Three subjects were dosed with OCU410 in the phase 1/2 study, Ocugen ( OCGN ) said, adding that three more will receive the medium dose in a second group.

The "positive" review by Data and Safety Monitoring Board "significantly builds on the favorable safety and tolerability profile exhibited by OCU410," said Ocugen's ( OCGN ) chief medical officer Huma Qamar.

The company's shares were rising past 8% in recent trading.

Price: 1.64, Change: +0.13, Percent Change: +8.28